Lupin Pharmaceuticals’ smooth-run in Japan; all eyes on biosimilars growth

which would come from biosimilars and it expects nearly 50 per cent of its Japan sales to come from the speciality business. Lupin’s Japan story assumes significance as it held on to the highly regulated market, when most of its Indian peers quit.
( read original story …)